 | • レポートコード：GIR-107A12345 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、101ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、ホルモン不応性乳がんのグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。ホルモン不応性乳がんの種類別市場規模（腫瘍マーカー療法、遺伝子発現療法、遺伝子突然変異療法）、用途別市場規模（科学研究・生産、生物科学・技術、医療技術、医療機器・装置）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・ホルモン不応性乳がんの市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：AstraZeneca、AmpliMed Corporation、Roche、Bluefish Pharmaceuticals AB、NeoCorp、Sanofi Genzyme、Neopharm、Boehringer Ingelheim GmbH ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：腫瘍マーカー療法、遺伝子発現療法、遺伝子突然変異療法 ・用途別分析2016年-2026年：科学研究・生産、生物科学・技術、医療技術、医療機器・装置 ・ホルモン不応性乳がんの北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・ホルモン不応性乳がんのヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・ホルモン不応性乳がんのアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・ホルモン不応性乳がんの南米市場規模2016年-2026年：ブラジル、アルゼンチン ・ホルモン不応性乳がんの中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Hormone Refractory Breast Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Hormone Refractory Breast Cancer size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Hormone Refractory Breast Cancer market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Hormone Refractory Breast Cancer market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Tumor Markers Therapy
Gene Expression Therapy
Gene Mutation Therapy
Market segment by Application, can be divided into
Scientific Research and Production
Biological Science and Technology
Medical Technology
Medical Apparatus and Instruments
Market segment by players, this report covers
AstraZeneca
AmpliMed Corporation
Roche
Bluefish Pharmaceuticals AB
NeoCorp
Sanofi Genzyme
Neopharm
Boehringer Ingelheim GmbH
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Hormone Refractory Breast Cancer
1.2 Classification of Hormone Refractory Breast Cancer by Type
1.2.1 Overview: Global Hormone Refractory Breast Cancer Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Hormone Refractory Breast Cancer Revenue Market Share by Type in 2020
1.2.3 Tumor Markers Therapy
1.2.4 Gene Expression Therapy
1.2.5 Gene Mutation Therapy
1.3 Global Hormone Refractory Breast Cancer Market by Application
1.3.1 Overview: Global Hormone Refractory Breast Cancer Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Scientific Research and Production
1.3.3 Biological Science and Technology
1.3.4 Medical Technology
1.3.5 Medical Apparatus and Instruments
1.4 Global Hormone Refractory Breast Cancer Market Size & Forecast
1.5 Global Hormone Refractory Breast Cancer Market Size and Forecast by Region
1.5.1 Global Hormone Refractory Breast Cancer Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Hormone Refractory Breast Cancer Market Size by Region, (2016-2021)
1.5.3 North America Hormone Refractory Breast Cancer Market Size and Prospect (2016-2026)
1.5.4 Europe Hormone Refractory Breast Cancer Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Hormone Refractory Breast Cancer Market Size and Prospect (2016-2026)
1.5.6 South America Hormone Refractory Breast Cancer Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Hormone Refractory Breast Cancer Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Hormone Refractory Breast Cancer Market Drivers
1.6.2 Hormone Refractory Breast Cancer Market Restraints
1.6.3 Hormone Refractory Breast Cancer Trends Analysis
2 Company Profiles
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business
2.1.3 AstraZeneca Hormone Refractory Breast Cancer Product and Solutions
2.1.4 AstraZeneca Hormone Refractory Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 AstraZeneca Recent Developments and Future Plans
2.2 AmpliMed Corporation
2.2.1 AmpliMed Corporation Details
2.2.2 AmpliMed Corporation Major Business
2.2.3 AmpliMed Corporation Hormone Refractory Breast Cancer Product and Solutions
2.2.4 AmpliMed Corporation Hormone Refractory Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 AmpliMed Corporation Recent Developments and Future Plans
2.3 Roche
2.3.1 Roche Details
2.3.2 Roche Major Business
2.3.3 Roche Hormone Refractory Breast Cancer Product and Solutions
2.3.4 Roche Hormone Refractory Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Roche Recent Developments and Future Plans
2.4 Bluefish Pharmaceuticals AB
2.4.1 Bluefish Pharmaceuticals AB Details
2.4.2 Bluefish Pharmaceuticals AB Major Business
2.4.3 Bluefish Pharmaceuticals AB Hormone Refractory Breast Cancer Product and Solutions
2.4.4 Bluefish Pharmaceuticals AB Hormone Refractory Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Bluefish Pharmaceuticals AB Recent Developments and Future Plans
2.5 NeoCorp
2.5.1 NeoCorp Details
2.5.2 NeoCorp Major Business
2.5.3 NeoCorp Hormone Refractory Breast Cancer Product and Solutions
2.5.4 NeoCorp Hormone Refractory Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 NeoCorp Recent Developments and Future Plans
2.6 Sanofi Genzyme
2.6.1 Sanofi Genzyme Details
2.6.2 Sanofi Genzyme Major Business
2.6.3 Sanofi Genzyme Hormone Refractory Breast Cancer Product and Solutions
2.6.4 Sanofi Genzyme Hormone Refractory Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Sanofi Genzyme Recent Developments and Future Plans
2.7 Neopharm
2.7.1 Neopharm Details
2.7.2 Neopharm Major Business
2.7.3 Neopharm Hormone Refractory Breast Cancer Product and Solutions
2.7.4 Neopharm Hormone Refractory Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Neopharm Recent Developments and Future Plans
2.8 Boehringer Ingelheim GmbH
2.8.1 Boehringer Ingelheim GmbH Details
2.8.2 Boehringer Ingelheim GmbH Major Business
2.8.3 Boehringer Ingelheim GmbH Hormone Refractory Breast Cancer Product and Solutions
2.8.4 Boehringer Ingelheim GmbH Hormone Refractory Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Boehringer Ingelheim GmbH Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Hormone Refractory Breast Cancer Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Hormone Refractory Breast Cancer Players Market Share
3.2.2 Top 10 Hormone Refractory Breast Cancer Players Market Share
3.2.3 Market Competition Trend
3.3 Hormone Refractory Breast Cancer Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Hormone Refractory Breast Cancer Revenue and Market Share by Type (2016-2021)
4.2 Global Hormone Refractory Breast Cancer Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Hormone Refractory Breast Cancer Revenue Market Share by Application (2016-2021)
5.2 Hormone Refractory Breast Cancer Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Hormone Refractory Breast Cancer Revenue by Type (2016-2026)
6.2 North America Hormone Refractory Breast Cancer Revenue by Application (2016-2026)
6.3 North America Hormone Refractory Breast Cancer Market Size by Country
6.3.1 North America Hormone Refractory Breast Cancer Revenue by Country (2016-2026)
6.3.2 United States Hormone Refractory Breast Cancer Market Size and Forecast (2016-2026)
6.3.3 Canada Hormone Refractory Breast Cancer Market Size and Forecast (2016-2026)
6.3.4 Mexico Hormone Refractory Breast Cancer Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Hormone Refractory Breast Cancer Revenue by Type (2016-2026)
7.2 Europe Hormone Refractory Breast Cancer Revenue by Application (2016-2026)
7.3 Europe Hormone Refractory Breast Cancer Market Size by Country
7.3.1 Europe Hormone Refractory Breast Cancer Revenue by Country (2016-2026)
7.3.2 Germany Hormone Refractory Breast Cancer Market Size and Forecast (2016-2026)
7.3.3 France Hormone Refractory Breast Cancer Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Hormone Refractory Breast Cancer Market Size and Forecast (2016-2026)
7.3.5 Russia Hormone Refractory Breast Cancer Market Size and Forecast (2016-2026)
7.3.6 Italy Hormone Refractory Breast Cancer Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Hormone Refractory Breast Cancer Revenue by Type (2016-2026)
8.2 Asia-Pacific Hormone Refractory Breast Cancer Revenue by Application (2016-2026)
8.3 Asia-Pacific Hormone Refractory Breast Cancer Market Size by Region
8.3.1 Asia-Pacific Hormone Refractory Breast Cancer Revenue by Region (2016-2026)
8.3.2 China Hormone Refractory Breast Cancer Market Size and Forecast (2016-2026)
8.3.3 Japan Hormone Refractory Breast Cancer Market Size and Forecast (2016-2026)
8.3.4 South Korea Hormone Refractory Breast Cancer Market Size and Forecast (2016-2026)
8.3.5 India Hormone Refractory Breast Cancer Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Hormone Refractory Breast Cancer Market Size and Forecast (2016-2026)
8.3.7 Australia Hormone Refractory Breast Cancer Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Hormone Refractory Breast Cancer Revenue by Type (2016-2026)
9.2 South America Hormone Refractory Breast Cancer Revenue by Application (2016-2026)
9.3 South America Hormone Refractory Breast Cancer Market Size by Country
9.3.1 South America Hormone Refractory Breast Cancer Revenue by Country (2016-2026)
9.3.2 Brazil Hormone Refractory Breast Cancer Market Size and Forecast (2016-2026)
9.3.3 Argentina Hormone Refractory Breast Cancer Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Hormone Refractory Breast Cancer Revenue by Type (2016-2026)
10.2 Middle East & Africa Hormone Refractory Breast Cancer Revenue by Application (2016-2026)
10.3 Middle East & Africa Hormone Refractory Breast Cancer Market Size by Country
10.3.1 Middle East & Africa Hormone Refractory Breast Cancer Revenue by Country (2016-2026)
10.3.2 Turkey Hormone Refractory Breast Cancer Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Hormone Refractory Breast Cancer Market Size and Forecast (2016-2026)
10.3.4 UAE Hormone Refractory Breast Cancer Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Hormone Refractory Breast Cancer Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Hormone Refractory Breast Cancer Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Hormone Refractory Breast Cancer Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Hormone Refractory Breast Cancer Revenue (USD Million) by Region (2016-2021)
Table 5. Global Hormone Refractory Breast Cancer Revenue Market Share by Region (2021-2026)
Table 6. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 7. AstraZeneca Major Business
Table 8. AstraZeneca Hormone Refractory Breast Cancer Product and Solutions
Table 9. AstraZeneca Hormone Refractory Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. AmpliMed Corporation Corporate Information, Head Office, and Major Competitors
Table 11. AmpliMed Corporation Major Business
Table 12. AmpliMed Corporation Hormone Refractory Breast Cancer Product and Solutions
Table 13. AmpliMed Corporation Hormone Refractory Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Roche Corporate Information, Head Office, and Major Competitors
Table 15. Roche Major Business
Table 16. Roche Hormone Refractory Breast Cancer Product and Solutions
Table 17. Roche Hormone Refractory Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Bluefish Pharmaceuticals AB Corporate Information, Head Office, and Major Competitors
Table 19. Bluefish Pharmaceuticals AB Major Business
Table 20. Bluefish Pharmaceuticals AB Hormone Refractory Breast Cancer Product and Solutions
Table 21. Bluefish Pharmaceuticals AB Hormone Refractory Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. NeoCorp Corporate Information, Head Office, and Major Competitors
Table 23. NeoCorp Major Business
Table 24. NeoCorp Hormone Refractory Breast Cancer Product and Solutions
Table 25. NeoCorp Hormone Refractory Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Sanofi Genzyme Corporate Information, Head Office, and Major Competitors
Table 27. Sanofi Genzyme Major Business
Table 28. Sanofi Genzyme Hormone Refractory Breast Cancer Product and Solutions
Table 29. Sanofi Genzyme Hormone Refractory Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Neopharm Corporate Information, Head Office, and Major Competitors
Table 31. Neopharm Major Business
Table 32. Neopharm Hormone Refractory Breast Cancer Product and Solutions
Table 33. Neopharm Hormone Refractory Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Boehringer Ingelheim GmbH Corporate Information, Head Office, and Major Competitors
Table 35. Boehringer Ingelheim GmbH Major Business
Table 36. Boehringer Ingelheim GmbH Hormone Refractory Breast Cancer Product and Solutions
Table 37. Boehringer Ingelheim GmbH Hormone Refractory Breast Cancer Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Global Hormone Refractory Breast Cancer Revenue (USD Million) by Players (2019-2021)
Table 39. Global Hormone Refractory Breast Cancer Revenue Share by Players (2019-2021)
Table 40. Breakdown of Hormone Refractory Breast Cancer by Company Type (Tier 1, Tier 2 and Tier 3)
Table 41. Hormone Refractory Breast Cancer Players Head Office, Products and Services Provided
Table 42. Hormone Refractory Breast Cancer Mergers & Acquisitions in the Past Five Years
Table 43. Hormone Refractory Breast Cancer New Entrants and Expansion Plans
Table 44. Global Hormone Refractory Breast Cancer Revenue (USD Million) by Type (2016-2021)
Table 45. Global Hormone Refractory Breast Cancer Revenue Share by Type (2016-2021)
Table 46. Global Hormone Refractory Breast Cancer Revenue Forecast by Type (2021-2026)
Table 47. Global Hormone Refractory Breast Cancer Revenue by Application (2016-2021)
Table 48. Global Hormone Refractory Breast Cancer Revenue Forecast by Application (2021-2026)
Table 49. North America Hormone Refractory Breast Cancer Revenue by Type (2016-2021) & (USD Million)
Table 50. North America Hormone Refractory Breast Cancer Revenue by Type (2021-2026) & (USD Million)
Table 51. North America Hormone Refractory Breast Cancer Revenue by Application (2016-2021) & (USD Million)
Table 52. North America Hormone Refractory Breast Cancer Revenue by Application (2021-2026) & (USD Million)
Table 53. North America Hormone Refractory Breast Cancer Revenue by Country (2016-2021) & (USD Million)
Table 54. North America Hormone Refractory Breast Cancer Revenue by Country (2021-2026) & (USD Million)
Table 55. Europe Hormone Refractory Breast Cancer Revenue by Type (2016-2021) & (USD Million)
Table 56. Europe Hormone Refractory Breast Cancer Revenue by Type (2021-2026) & (USD Million)
Table 57. Europe Hormone Refractory Breast Cancer Revenue by Application (2016-2021) & (USD Million)
Table 58. Europe Hormone Refractory Breast Cancer Revenue by Application (2021-2026) & (USD Million)
Table 59. Europe Hormone Refractory Breast Cancer Revenue by Country (2016-2021) & (USD Million)
Table 60. Europe Hormone Refractory Breast Cancer Revenue by Country (2021-2026) & (USD Million)
Table 61. Asia-Pacific Hormone Refractory Breast Cancer Revenue by Type (2016-2021) & (USD Million)
Table 62. Asia-Pacific Hormone Refractory Breast Cancer Revenue by Type (2021-2026) & (USD Million)
Table 63. Asia-Pacific Hormone Refractory Breast Cancer Revenue by Application (2016-2021) & (USD Million)
Table 64. Asia-Pacific Hormone Refractory Breast Cancer Revenue by Application (2021-2026) & (USD Million)
Table 65. Asia-Pacific Hormone Refractory Breast Cancer Revenue by Region (2016-2021) & (USD Million)
Table 66. Asia-Pacific Hormone Refractory Breast Cancer Revenue by Region (2021-2026) & (USD Million)
Table 67. South America Hormone Refractory Breast Cancer Revenue by Type (2016-2021) & (USD Million)
Table 68. South America Hormone Refractory Breast Cancer Revenue by Type (2021-2026) & (USD Million)
Table 69. South America Hormone Refractory Breast Cancer Revenue by Application (2016-2021) & (USD Million)
Table 70. South America Hormone Refractory Breast Cancer Revenue by Application (2021-2026) & (USD Million)
Table 71. South America Hormone Refractory Breast Cancer Revenue by Country (2016-2021) & (USD Million)
Table 72. South America Hormone Refractory Breast Cancer Revenue by Country (2021-2026) & (USD Million)
Table 73. Middle East & Africa Hormone Refractory Breast Cancer Revenue by Type (2016-2021) & (USD Million)
Table 74. Middle East & Africa Hormone Refractory Breast Cancer Revenue by Type (2021-2026) & (USD Million)
Table 75. Middle East & Africa Hormone Refractory Breast Cancer Revenue by Application (2016-2021) & (USD Million)
Table 76. Middle East & Africa Hormone Refractory Breast Cancer Revenue by Application (2021-2026) & (USD Million)
Table 77. Middle East & Africa Hormone Refractory Breast Cancer Revenue by Country (2016-2021) & (USD Million)
Table 78. Middle East & Africa Hormone Refractory Breast Cancer Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Hormone Refractory Breast Cancer Picture
Figure 2. Global Hormone Refractory Breast Cancer Revenue Market Share by Type in 2020
Figure 3. Tumor Markers Therapy
Figure 4. Gene Expression Therapy
Figure 5. Gene Mutation Therapy
Figure 6. Hormone Refractory Breast Cancer Revenue Market Share by Application in 2020
Figure 7. Scientific Research and Production Picture
Figure 8. Biological Science and Technology Picture
Figure 9. Medical Technology Picture
Figure 10. Medical Apparatus and Instruments Picture
Figure 11. Global Hormone Refractory Breast Cancer Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 12. Global Hormone Refractory Breast Cancer Revenue and Forecast (2016-2026) & (USD Million)
Figure 13. Global Hormone Refractory Breast Cancer Revenue Market Share by Region (2016-2026)
Figure 14. Global Hormone Refractory Breast Cancer Revenue Market Share by Region in 2020
Figure 15. North America Hormone Refractory Breast Cancer Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Europe Hormone Refractory Breast Cancer Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Asia-Pacific Hormone Refractory Breast Cancer Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. South America Hormone Refractory Breast Cancer Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Middle East and Africa Hormone Refractory Breast Cancer Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Hormone Refractory Breast Cancer Market Drivers
Figure 21. Hormone Refractory Breast Cancer Market Restraints
Figure 22. Hormone Refractory Breast Cancer Market Trends
Figure 23. AstraZeneca Recent Developments and Future Plans
Figure 24. AmpliMed Corporation Recent Developments and Future Plans
Figure 25. Roche Recent Developments and Future Plans
Figure 26. Bluefish Pharmaceuticals AB Recent Developments and Future Plans
Figure 27. NeoCorp Recent Developments and Future Plans
Figure 28. Sanofi Genzyme Recent Developments and Future Plans
Figure 29. Neopharm Recent Developments and Future Plans
Figure 30. Boehringer Ingelheim GmbH Recent Developments and Future Plans
Figure 31. Global Hormone Refractory Breast Cancer Revenue Share by Players in 2020
Figure 32. Hormone Refractory Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 33. Global Top 3 Players Hormone Refractory Breast Cancer Revenue Market Share in 2020
Figure 34. Global Top 10 Players Hormone Refractory Breast Cancer Revenue Market Share in 2020
Figure 35. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 36. Global Hormone Refractory Breast Cancer Revenue Share by Type in 2020
Figure 37. Global Hormone Refractory Breast Cancer Market Share Forecast by Type (2021-2026)
Figure 38. Global Hormone Refractory Breast Cancer Revenue Share by Application in 2020
Figure 39. Global Hormone Refractory Breast Cancer Market Share Forecast by Application (2021-2026)
Figure 40. North America Hormone Refractory Breast Cancer Sales Market Share by Type (2016-2026)
Figure 41. North America Hormone Refractory Breast Cancer Sales Market Share by Application (2016-2026)
Figure 42. North America Hormone Refractory Breast Cancer Revenue Market Share by Country (2016-2026)
Figure 43. United States Hormone Refractory Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. Canada Hormone Refractory Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Mexico Hormone Refractory Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Europe Hormone Refractory Breast Cancer Sales Market Share by Type (2016-2026)
Figure 47. Europe Hormone Refractory Breast Cancer Sales Market Share by Application (2016-2026)
Figure 48. Europe Hormone Refractory Breast Cancer Revenue Market Share by Country (2016-2026)
Figure 49. Germany Hormone Refractory Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. France Hormone Refractory Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. United Kingdom Hormone Refractory Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Russia Hormone Refractory Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Italy Hormone Refractory Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Asia-Pacific Hormone Refractory Breast Cancer Sales Market Share by Type (2016-2026)
Figure 55. Asia-Pacific Hormone Refractory Breast Cancer Sales Market Share by Application (2016-2026)
Figure 56. Asia-Pacific Hormone Refractory Breast Cancer Revenue Market Share by Region (2016-2026)
Figure 57. China Hormone Refractory Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Japan Hormone Refractory Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. South Korea Hormone Refractory Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. India Hormone Refractory Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Southeast Asia Hormone Refractory Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Australia Hormone Refractory Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. South America Hormone Refractory Breast Cancer Sales Market Share by Type (2016-2026)
Figure 64. South America Hormone Refractory Breast Cancer Sales Market Share by Application (2016-2026)
Figure 65. South America Hormone Refractory Breast Cancer Revenue Market Share by Country (2016-2026)
Figure 66. Brazil Hormone Refractory Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Argentina Hormone Refractory Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Middle East and Africa Hormone Refractory Breast Cancer Sales Market Share by Type (2016-2026)
Figure 69. Middle East and Africa Hormone Refractory Breast Cancer Sales Market Share by Application (2016-2026)
Figure 70. Middle East and Africa Hormone Refractory Breast Cancer Revenue Market Share by Country (2016-2026)
Figure 71. Turkey Hormone Refractory Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Saudi Arabia Hormone Refractory Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. UAE Hormone Refractory Breast Cancer Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Methodology
Figure 75. Research Process and Data Source
ホルモン抵抗性乳がんの世界市場 2019年版：種類別（腫瘍マーカー療法、遺伝子発現療法、遺伝子突然変異療法）、用途別（科学研究および生産、生物科学技術、医療技術、医療機器および器具） Scope of the Report: The global Hormone Refractory Breast Cancer market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especially in…- ホルモン抵抗性前立腺がん（HRPCA）市場：世界及び中国市場分析・予測（～2024年） Hormone Refractory Prostate Cancer (HRPCA) Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Hormone Refractory Prostate Cancer (HRPCA) industry with a focus on the Chinese market. The report provides key statistics on the marke…
- 世界のがんホルモン療法剤市場 2021：企業別、地域別、種類・用途別 The Cancer Hormone Therapy Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade re…
- 世界のがんホルモン療法薬市場予測（～2024年） Hormone Therapy, (also called hormonal therapy, hormone treatment, or endocrine therapy) is a cancer treatment that blocks or lowers the growth of cancer that uses hormones to grow. Doctors use it to treat some cancers such as breast and prostate cancer. Scope of the Report: The global Cancer Hormon…
- 世界の乳がん診断・薬物技術市場 2021：企業別、地域別、種類・用途別 The Breast Cancer Diagnostic and Drug Technologies market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain opti…